THOUSAND OAKS, Calif. and COLLEGEVILLE, Pa., Feb. 4, 2011 /PRNewswire/ -- Amgen (Nasdaq: AMGN) and Pfizer Inc. (NYSE: PFE) today announced results from a new trial that demonstrated Enbrel® ...
During Period one, patients received open-label ENBREL 50mg QW plus MTX for 36 weeks. Those who responded to treatment (n=604; DAS28 <3.2 at week 36 and an average DAS28 <3.2 from week 12 through 36) ...
SEATTLE, WA – Immunex Corporation (Nasdaq: IMNX) and Wyeth-Ayerst Laboratories, a division of American Home Products (NYSE: AHP) announced today that the U.S. Food and Drug Administration (FDA) has ...
THOUSAND OAKS, Calif. and NEW YORK, May 25, 2011 /PRNewswire/ -- Amgen (NASDAQ: AMGN) and Pfizer Inc. (NYSE: PFE) today announced new results from multiple studies of ENBREL, further expanding the ...
THOUSAND OAKS, Calif., and RADNOR, Penn., – Results from a study of ENBREL® (etanercept), the only fully human TNF receptor, were presented demonstrating significant inhibition in the progression of ...
Whether starting or maintaining treatment, the Embark App has multiple features that can help patients on ENBREL throughout their treatment experience. As the healthcare industry continues to evolve ...
Amgen and Wyeth have announced that the prescribing information for Enbrel (etanercept) has been updated. The previously bolded warning relating to the risk of infections and tuberculosis (TB) is now ...
DUBLIN--(BUSINESS WIRE)--The "Enbrel - Drug Insight, 2019" report has been added to ResearchAndMarkets.com's offering. Enbrel Drug Insight, 2019 highlights the drug marketed details and the Global API ...
March 18, 2008 — A black box warning has been issued for etanercept (Enbrel, manufactured by Immunex Corporation; marketed by Amgen and Wyeth Pharmaceuticals) regarding the risk for tuberculosis and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results